Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 27, 590–591 (1 July 2009) | doi:10.1038/nbt0709-590
iZumi's plans to capitalize on iPS cells
Abstract
iZumi Bio, of S. San Francisco, California, launched quietly in 2007 as excitement about induced pluripotent stem (iPS) cells was reaching fever pitch. In this profile, iZumi CEO John Walker and Beth Seidenberg of iZumi investor Kleiner Perkins Caufield & Byers (KPCB) (Box 1) talk to Nature Biotechnology about the West Coast startup and its goal of turning iPS cells into a profitable business.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
